Adeno‐Associated Virus‐Induced Humanized Hypertensive Mouse Model Validates N‐Acetylgalactosamine‐Conjugated Small Interfering RNA Targeting Angiotensinogen as a Long‐Acting Antihypertensive Therapy
BACKGROUND: Hypertension remains a leading cause of global morbidity and mortality, yet current therapeutic strategies lack sustained efficacy and long-term stability. Our study aimed to construct a humanized rodent model for drugs development especially currently prevalent small interfering RNA medication. METHODS: A humanized hypertensive mouse model was generated by subcutaneous injection of neonatal mice with adeno-associated viruses encoding hAGT (human angiotensinogen) and hRENIN (human renin). Blood pressure was monitored weekly via tail-cuff plethysmography. Expression of hAGT and hRENIN was assessed by ELISA, Western blot, and reverse transcription quantitative polymerase chain reaction. Cardiac function was evaluated by echocardiography at 4 and 6 months postinjection. Hypertension-associated comorbidities were examined through histological analysis and ELISA. A modified N-acetylgalactosamine-conjugated small interfering RNA targeting human hepatic AGT (GalNAc-siAGT) was screened and subcutaneously administered to humanized hypertensive mice, either alone or in combination with valsartan, to evaluate therapeutic efficacy. RESULTS: The dual adeno-associated virus-induced humanized hypertensive model exhibited a sustained hypertension for 6 months and manifested prevalent comorbidities, including heart failure and kidney disease. This modified GalNAc-siAGT demonstrated significant activity in knocking down hAGT both in vitro and in vivo. Only a single subcutaneous injection of GalNAc-siAGT in humanized hypertensive mice led to a sustained reduction in blood pressure lasting for 2 months, accompanied by cardio- and renoprotective effects. Moreover, combining GalNAc-siAGT with the renin-angiotensin system blocker, valsartan, significantly enhanced therapeutic efficacy. CONCLUSIONS: Our study validated the antihypertensive therapeutic effect of GalNAc-siAGT in a humanized hypertensive murine model while highlighting the translational potential of this model for clinical drug development.
Authors
- Xiaoling Guo (ORCID: https://orcid.org/0000-0003-3153-6249)
- Tingting Liu (ORCID: https://orcid.org/0000-0003-2756-9697)
- Junhao Xiong (ORCID: https://orcid.org/0009-0009-2692-4563)
- 吴连拼
- Dan Zhu (ORCID: https://orcid.org/0000-0001-6241-4354)
- Bing Zhang (ORCID: https://orcid.org/0000-0002-8836-7178)
- Kang Cheng (ORCID: https://orcid.org/0000-0002-7645-7811)
- Ruogu Li (ORCID: https://orcid.org/0000-0002-0608-524X)
- Juntao Lin
- Shasha Zhang
- Yuanzhe Sheng
- Xing Liu (ORCID: https://orcid.org/0009-0004-4546-8499)
Institutions
- Shanghai Jiao Tong University (CN)
- Shanghai Chest Hospital (CN)
- Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University (CN)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1161/jaha.125.046444
- Primary Topic
- Renin-Angiotensin System Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00